<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: It has been suggested that colorectal <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with or without microsatellite instability (MSI) can stimulate <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in different ways </plain></SENT>
<SENT sid="1" pm="."><plain>The vascular endothelial growth factor (VEGF) system is essential for the angiogenetic process and the growth of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumours</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to analyse the relationship between serum VEGF-A and the MSI status of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>METHOD: In the study, 249 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were divided into a test cohort of 83 patients and a validation cohort of 166 </plain></SENT>
<SENT sid="4" pm="."><plain>MSI was determined using immunohistochemistry </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumours</z:e> lacking protein expression of any of the four mismatch repair genes (MLH1, PMS2, MSH2 or MSH6) were labelled as high MSI </plain></SENT>
<SENT sid="6" pm="."><plain>The rest were considered to be microsatellite stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>The serum VEGF-A analyses were performed by ELISA </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> of 15 patients in the test cohort and 27 in the validation cohort were classified as MSI </plain></SENT>
<SENT sid="9" pm="."><plain>In the test cohort, patients with an MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> had a significantly higher median serum VEGF-A concentration [617 pg/ml (95% CI 445-863)], compared with patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>, [317 pg/ml (95% CI 224-386)], P = 0.01 </plain></SENT>
<SENT sid="10" pm="."><plain>A similar relationship was confirmed in the validation cohort, P = 0.04 </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: This study provides some evidence to suggest that patients with an MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> have higher serum VEGF-A levels than patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>If further validated, these findings could be of importance when considering the effects of anti-VEGF-A treatment </plain></SENT>
</text></document>